Nuo Therapeutics, Inc.
Data quality: 83%
AURX
OTC
Manufacturing
Measuring & Analyzing Instruments
$1.70
▲
$0.34
(24.71%)
Mkt Cap: 82.09 M
Price
$1.70
Mkt Cap
82.09 M
Day Range
$1.69 — $1.70
52-Week Range
$0.94 — $3.23
Volume
4,710
Open $1.69
50D / 200D Avg
$1.48
14.78% above
50D / 200D Avg
$1.84
7.36% below
Quick Summary
Key Takeaways
Negative free cash flow of -1.14 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC-385.42%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio1.16
Interest CoverageN/A
Valuation
PE (TTM)
-32.68
Below sector avg (-1.98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -32.7 | -2.0 |
| P/B | — | 5.1 |
| ROE % | — | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -2.51 M |
| ROE | N/A | ROA | -152.85% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -1.14 M |
| ROIC | -385.42% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.16 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 206,167 | Tangible Book Value | -419,606 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -32.68 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1.39% | ||
| Market Cap | 82.09 M | Enterprise Value | 81.58 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | N/A |
| FCF / Share | -0.02 | OCF / Share | -0.02 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 45.37% |
| SBC-Adj. FCF | -1.22 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -2.51 M | -2.32 M | -3.17 M | -3.17 M | -90,670.0 |
| EPS (Diluted) | — | — | — | — | -0.03 |
| Gross Profit | 2.22 M | 1.06 M | 482,433.0 | 93,036.0 | 0.0 |
| Operating Income | -2.52 M | -2.46 M | -3.17 M | -3.32 M | -90,670.0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | 0.0 |
| SG&A Expenses | 4.73 M | 3.52 M | 3.65 M | 3.41 M | — |
| D&A | — | — | — | — | 0.0 |
| Interest Expense | — | — | — | — | 0.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.85 M | 1.19 M | 1.88 M | 3.05 M | 1.47 M |
| Total Liabilities | 2.80 M | 675,796.0 | 838,732.0 | 856,022.0 | 673,079.0 |
| Shareholders' Equity | -956,559.0 | 513,712.0 | 1.04 M | 2.19 M | 792,839.0 |
| Total Debt | — | — | — | — | 0.0 |
| Cash & Equivalents | 548,946.0 | 283,714.0 | 928,681.0 | 2.05 M | 1.41 M |
| Current Assets | 1.38 M | 841,546.0 | 1.56 M | 2.63 M | 1.47 M |
| Current Liabilities | 1.31 M | 578,451.0 | 674,527.0 | 600,431.0 | 673,079.0 |
{"event":"ticker_viewed","properties":{"ticker":"AURX","listing_kind":"stock","pathname":"/stocks/aurx","exchange":"OTC","country":"US"}}